OCULAR THERAPEUTIX, INC (OCUL) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Win.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Win.
54/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 5 wins, 7 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinOCUL / S&P 15.94% / 15.20% |
LoseOCUL / S&P -8.14% / 15.00% |
LoseOCUL / S&P 10.24% / 50.40% |
| 2026-Q10/3 |
LoseOCUL / S&P -30.23% / -4.33% |
LoseOCUL / S&P -12.76% / 11.30% |
LoseOCUL / S&P 26.32% / 27.70% |
| 2025-Q42/3 |
WinOCUL / S&P 3.85% / 2.65% |
LoseOCUL / S&P -18.47% / 9.00% |
WinOCUL / S&P 13.60% / 13.40% |
| 2025-Q32/3 |
WinOCUL / S&P 25.97% / 8.12% |
LoseOCUL / S&P -9.21% / 4.61% |
WinOCUL / S&P 17.21% / 13.45% |
| 2025-Q21/3 |
WinOCUL / S&P 26.60% / 10.94% |
LoseOCUL / S&P -7.26% / 4.83% |
LoseOCUL / S&P 1.60% / 10.63% |
| 2025-Q10/3 |
LoseOCUL / S&P -14.17% / -4.27% |
LoseOCUL / S&P -0.33% / 4.98% |
LoseOCUL / S&P -8.80% / 10.57% |
| 2024-Q42/3 |
LoseOCUL / S&P -1.84% / 2.41% |
WinOCUL / S&P 9.03% / 5.25% |
WinOCUL / S&P 8.70% / 6.15% |
| 2024-Q33/3 |
WinOCUL / S&P 27.19% / 5.89% |
WinOCUL / S&P 6.45% / 5.89% |
WinOCUL / S&P 7.02% / 6.11% |
| 2024-Q21/3 |
LoseOCUL / S&P -24.84% / 4.28% |
WinOCUL / S&P 11.90% / 5.38% |
LoseOCUL / S&P 4.17% / 5.12% |
| 2024-Q12/3 |
WinOCUL / S&P 104.04% / 10.56% |
WinOCUL / S&P 15.79% / 5.71% |
LoseOCUL / S&P 5.04% / 5.59% |
| 2023-Q43/3 |
WinOCUL / S&P 42.04% / 11.69% |
WinOCUL / S&P 13.50% / 6.81% |
WinOCUL / S&P 12.75% / 7.78% |
| 2023-Q32/3 |
LoseOCUL / S&P -39.15% / -3.27% |
WinOCUL / S&P 16.07% / 7.52% |
WinOCUL / S&P 12.87% / -5.03% |
| 2023-Q21/3 |
LoseOCUL / S&P -2.09% / 8.74% |
LoseOCUL / S&P 9.39% / 9.50% |
WinOCUL / S&P 29.03% / -8.57% |
| 2023-Q12/3 |
WinOCUL / S&P 87.54% / 7.50% |
LoseOCUL / S&P 4.69% / 10.77% |
WinOCUL / S&P 27.96% / -15.69% |
| 2022-Q42/3 |
LoseOCUL / S&P -32.29% / 7.56% |
WinOCUL / S&P 18.32% / 11.88% |
WinOCUL / S&P 7.37% / -17.99% |
| 2022-Q32/3 |
WinOCUL / S&P 3.23% / -4.88% |
WinOCUL / S&P 28.95% / 13.47% |
LoseOCUL / S&P -50.97% / -1.41% |
| 2022-Q21/3 |
LoseOCUL / S&P -18.79% / -16.10% |
WinOCUL / S&P 54.60% / 13.71% |
LoseOCUL / S&P -54.41% / 11.04% |
| 2022-Q11/3 |
LoseOCUL / S&P -28.98% / -4.60% |
WinOCUL / S&P 123.01% / 15.97% |
LoseOCUL / S&P -61.73% / 42.23% |
| 2021-Q41/3 |
LoseOCUL / S&P -30.30% / 11.03% |
WinOCUL / S&P 150.08% / 15.00% |
LoseOCUL / S&P -63.46% / 96.40% |
| 2021-Q31/3 |
LoseOCUL / S&P -29.48% / 0.58% |
WinOCUL / S&P 213.26% / 10.77% |
LoseOCUL / S&P 14.44% / 69.42% |
| 2021-Q21/3 |
LoseOCUL / S&P -13.59% / 8.55% |
WinOCUL / S&P 344.51% / 6.58% |
LoseOCUL / S&P 0.00% / 51.81% |
| 2021-Q11/3 |
LoseOCUL / S&P -20.72% / 6.17% |
WinOCUL / S&P 248.93% / -1.06% |
LoseOCUL / S&P OCUL unavailable / 7.39% |
| 2020-Q42/3 |
WinOCUL / S&P 172.01% / 12.15% |
WinOCUL / S&P 311.71% / -3.72% |
LoseOCUL / S&P OCUL unavailable / -33.42% |
| 2020-Q31/3 |
LoseOCUL / S&P -8.64% / 8.93% |
WinOCUL / S&P 397.37% / -2.04% |
LoseOCUL / S&P OCUL unavailable / -27.10% |
| 2020-Q22/3 |
WinOCUL / S&P 68.28% / 20.54% |
WinOCUL / S&P 238.76% / -0.46% |
LoseOCUL / S&P OCUL unavailable / -27.11% |
| 2020-Q12/3 |
WinOCUL / S&P 25.32% / -19.60% |
WinOCUL / S&P 196.17% / 3.47% |
LoseOCUL / S&P OCUL unavailable / -14.75% |
| 2019-Q42/3 |
WinOCUL / S&P 29.93% / 9.07% |
WinOCUL / S&P 112.41% / 5.36% |
LoseOCUL / S&P OCUL unavailable / 2.99% |
| 2019-Q31/3 |
LoseOCUL / S&P -30.91% / 1.70% |
WinOCUL / S&P 25.44% / 5.02% |
LoseOCUL / S&P OCUL unavailable / 0.21% |
| 2019-Q22/3 |
WinOCUL / S&P 10.83% / 4.30% |
WinOCUL / S&P 7.31% / 6.64% |
LoseOCUL / S&P OCUL unavailable / 8.65% |
| 2019-Q11/3 |
LoseOCUL / S&P -0.25% / 13.65% |
WinOCUL / S&P 19.80% / 8.12% |
LoseOCUL / S&P OCUL unavailable / 14.29% |
| 2018-Q40/3 |
LoseOCUL / S&P -42.15% / -13.52% |
LoseOCUL / S&P 3.48% / 9.05% |
LoseOCUL / S&P OCUL unavailable / 18.23% |
| 2018-Q30/3 |
LoseOCUL / S&P 1.93% / 7.71% |
LoseOCUL / S&P 1.34% / 10.21% |
LoseOCUL / S&P OCUL unavailable / 19.06% |
| 2018-Q21/3 |
WinOCUL / S&P 3.69% / 3.43% |
LoseOCUL / S&P 5.10% / 9.03% |
LoseOCUL / S&P OCUL unavailable / 14.46% |
| 2018-Q11/3 |
WinOCUL / S&P 46.29% / -0.76% |
LoseOCUL / S&P -6.09% / 7.68% |
LoseOCUL / S&P OCUL unavailable / 12.46% |
| 2017-Q40/3 |
LoseOCUL / S&P -27.99% / 6.64% |
LoseOCUL / S&P 1.91% / 7.03% |
LoseOCUL / S&P OCUL unavailable / 13.82% |
| 2017-Q31/3 |
LoseOCUL / S&P -33.33% / 4.48% |
WinOCUL / S&P 7.45% / 5.68% |
LoseOCUL / S&P OCUL unavailable / 17.57% |
| 2017-Q21/3 |
LoseOCUL / S&P -0.11% / 3.09% |
WinOCUL / S&P 7.77% / 4.83% |
LoseOCUL / S&P OCUL unavailable / 17.74% |
| 2017-Q12/3 |
WinOCUL / S&P 10.87% / 6.07% |
WinOCUL / S&P 6.85% / 3.67% |
LoseOCUL / S&P OCUL unavailable / 13.32% |
| 2016-Q42/3 |
WinOCUL / S&P 21.83% / 3.82% |
WinOCUL / S&P 7.83% / 2.09% |
LoseOCUL / S&P OCUL unavailable / 7.05% |
| 2016-Q31/3 |
WinOCUL / S&P 38.79% / 3.85% |
LoseOCUL / S&P -0.38% / 0.20% |
LoseOCUL / S&P OCUL unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | OCUL total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -11.38% | 20.78% |
| Annualized return | -11.38% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | OCUL total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 0.28% | 83.14% |
| Annualized return | 0.06% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | OCUL total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 70.13% | 319.30% |
| Annualized return | 5.46% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |